Complete this form for recipients whose primary disease, reported on the Disease Classification Form (Form 2402), is Hodgkin Lymphoma (HL) or non-Hodgkin Lymphoma (NHL). One exception is Waldenstrom’s macroglobulinemia / lymphoplasmacytic lymphoma, for which, a Waldenstrom’s Macroglobulinemia Form (Form 2019) will be completed instead.

Links to Sections of Form
Q1-20: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q21-35: Post-HCT or Post-Infusion Therapy
Q36-86: Disease Relapse or Progression Since the Date of Last Report
Q87-90: Disease Status at the Time of Evaluation for This Reporting Period

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
10/23/2020 2118: LYM Post-Infusion Data Modify Modified the guidance prior to question 7 by removing (struck out below) and adding (text in red below) the following information:
If testing was performed by any of these three methods on blood ,or bone marrow , or any other specimen s at the time of best response, report “Yes” and go to question 8. If testing by these methods was not done on blood or bone marrow at the time of best response or it is not known whether testing was performed, report “No” or “Unknown” respectively and go to question 21.
8/24/2020 2118: LYM Post-Infusion Data Add Blue instruction box added above questions 65 and 72 on how to report intrathecal and intraocular therapies when multiple are given in a single line: If a recipient receives multiple intrathecal / intraocular therapies as part of a single line of therapy, report each intrathecal / intraocular therapy as a separate line.
2/19/2020 2118: LYM Post-Infusion Data Modify Changed the instruction for for reporting question 89. This was previously updated in question 87 (see below) but modified the following instruction to question 89 (for additional clarity) by removing (strike through) and adding (red) text as indicated below.
The center does not need to repeat all disease-specific assessments (biopsies, i.e., CT (radiographic) or PET scans, labs) each reporting period in order to complete current disease status data fields. Once a particular disease status is achieved, the center can continue reporting that disease status (based on labs / clinical assessments) until there is evidence of relapse / progression. If a disease-specific assessment did not occur during this time period, please report the date of any disease related assessment (e.g. clinical assessments, labs, etc.) as the date assessed (Q88 or Q90) regardless of what the parent question states about the specific CT (radiographic) or PET criteria.
2/19/2020 2118: LYM Post-Infusion Data Add Added guidance in Disease Assessment at the Time of Best Response to HCT or Cellular Therapy, after question 1, on scenarios where the form is completed for both the cellular therapy and HCT tracks.
9/20/2018 2118: LYM Post-Infusion Data Modify Changed the instruction for for reporting questions 88 and 89 by removing (strike through) and adding (red) text as indicated below.
The center does not need to repeat all disease-specific assessments (biopsies, i.e., CT (radiographic) or PET scans, labs) each reporting period in order to complete current disease status data fields. Once a particular disease status is achieved, the center can continue reporting that disease status (based on labs / clinical assessments) until there is evidence of relapse / progression. If a disease-specific assessment did not occur during this time period, please report the date of any disease related assessment (e.g. clinical assessments, labs, etc.) as the date assessed (Q88 or Q90) regardless of what the parent question states about the specific CT (radiographic) or PET criteria.
3/19/18 2118: LYM Post-Infusion Data Modify Change the instruction for question 89 by removing (strike through) and adding (red) text as indicated below.
The current disease status should reflect the most recent disease evaluations performed during the reporting period. Report “Not assessed” and submit the form if the recipient’s primary disease is a non-PET avid lymphoma or a PET scan was not performed during the reporting period since the infusion.
3/19/18 Comprehensive Disease Specific Manuals Add Added the following instruction for applicable post-infusion disease-specific forms where current disease status is asked (2110, 2111, 2112, 2113, 2114, 2115, 2116, 2118, 2119).
The center does not need to repeat all disease-specific assessments (biopsies, scans, labs) each reporting period in order to complete current disease status data fields. Once a particular disease status is achieved, the center can continue reporting that disease status (based on labs / clinical assessments) until there is evidence of relapse / progression.
1/30/18 2118: LYM Post-Infusion Data Modify Version 3 of the 2118: LYM Post-Infusion Data section of the Forms Instructions Manual released. Version 3 corresponds to revision 4 of the Form 2118.
Last modified: Nov 11, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.